BriaCell Therapeutics Corp. (BCTX, BCTXW) has experienced a 4.71% decline in stock value during Monday morning trading, following the announcement of a clinical response observed in a metastatic breast cancer patient treated with its innovative personalized immunotherapy, Bria-OTS. Although there was a positive outcome noted with the resolution of lung metastasis in one patient, the broader implications of the treatment have muted the impact of this news.
Currently, BCTX is trading at $4.78, reflecting a decrease of 4.71%, or $0.23, on the Nasdaq. The stock has seen significant volatility today, reaching a high of $7.87 and a low of $5.18, as investors have responded with caution to the announcement. The trading volume for the day stands at 13.3 million shares, far exceeding the average volume of 1.31 million.
Bria-OTS is undergoing a Phase 1/2a dose escalation study for metastatic recurrent breast cancer. This experimental therapy builds on BriaCell's primary candidate, Bria-IMT, which is currently in a pivotal Phase 3 study targeting metastatic breast cancer.
